ABSTRACT
Novo Nordisk is a Danish health care company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. The firm has more than 29,000 full-time employees in seventy-six countries (December, 2009) and markets its products in 179 countries. Approximately 46 percent of its employees are located in Denmark (13,433), with 54 percent in the rest of the world (North America, 4,076; Japan and Oceania, 1,010; international operations, 6,557; and Europe, 4,253); overall, 12 percent of the employees work in research and development, 30 percent in production and production administration, 42 percent in international sales and marketing, and 16 percent in administration.
